FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2972688853> ?p ?o ?g. }

• W2972688853 endingPage "6001" @default.
• W2972688853 startingPage "5976" @default.
• W2972688853 abstract "Strategies targeting cross-talk between immunosuppressive renal dendritic cells (DCs) and T regulatory cells (Tregs) may be effective in treating cisplatin (CDDP)-induced acute kidney injury (AKI). Galectin 3 (Gal-3), expressed on renal DCs, is known as a crucial regulator of immune response in the kidneys. In this study, we investigated the role of Gal-3 for DCs-mediated expansion of Tregs in the attenuation of CDDP-induced AKI. Methods: AKI was induced in CDDP-treated wild type (WT) C57BL/6 and Gal-3 deficient (Gal-3-/-) mice. Biochemical, histological analysis, enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, real-time PCR, magnetic cell sorting, flow cytometry and intracellular staining of renal-infiltrated immune cells were used to determine the differences between CDDP-treated WT and Gal-3-/- mice. Newly synthesized selective inhibitor of Gal-3 (Davanat) was used for pharmacological inhibition of Gal-3. Recombinant Gal-3 was used to demonstrate the effects of exogenously administered soluble Gal-3 on AKI progression. Pam3CSK4 was used for activation of Toll-like receptor (TLR)-2 in DCs. Cyclophosphamide or anti-CD25 antibody were used for the depletion of Tregs. 1-Methyl Tryptophan (1-MT) was used for pharmacological inhibition of Indoleamine 2,3-dioxygenase-1 (IDO1) in TLR-2-primed DCs which were afterwards used in passive transfer experiments. Results: CDDP-induced nephrotoxicity was significantly more aggravated in Gal-3-/- mice. Significantly reduced number of immunosuppressive TLR-2 and IDO1-expressing renal DCs, lower serum levels of KYN, decreased presence of IL-10-producing Tregs and significantly higher number of inflammatory IFN-γ and IL-17-producing neutrophils, Th1 and Th17 cells were observed in the CDDP-injured kidneys of Gal-3-/- mice. Pharmacological inhibitor of Gal-3 aggravated CDDP-induced AKI in WT animals while recombinant Gal-3 attenuated renal injury and inflammation in CDDP-treated Gal-3-/- mice. CDDP-induced apoptosis, driven by Bax and caspase-3, was aggravated in Gal-3-/- animals and in WT mice that received Gal-3 inhibitor (CDDP+Davanat-treated mice). Recombinant Gal-3 managed to completely attenuate CDDP-induced apoptosis in CDDP-injured kidneys of Gal-3-/- mice. Genetic deletion as well as pharmacological inhibition of Gal-3 in renal DCs remarkably reduced TLR-2-dependent activation of IDO1/KYN pathway in these cells diminishing their capacity to prevent transdifferentiation of Tregs in inflammatory Th1 and Th17 cells. Additionally, Tregs generated by Gal-3 deficient DCs were not able to suppress production of IFN-γ and IL-17 in activated neutrophils. TLR-2-primed DCs significantly enhanced capacity of Tregs for attenuation of CDDP-induced AKI and inflammation and expression of Gal-3 on TLR-2-primed DCs was crucially important for their capacity to enhance nephroprotective and immunosuppressive properties of Tregs. Adoptive transfer of TLR-2-primed WTDCs significantly expanded Tregs in the kidneys of CDDP-treated WT and Gal-3-/- recipients resulting in the suppression of IFN-γ and IL-17-driven inflammation and alleviation of AKI. Importantly, this phenomenon was not observed in CDDP-treated WT and Gal-3-/- recipients of TLR-2-primed Gal-3-/-DCs. Gal-3-dependent nephroprotective and immunosuppressive effects of renal DCs was due to the IDO1-induced expansion of renal Tregs since either inhibition of IDO1 activity in TLR-2-primed DCs or depletion of Tregs completely diminished DCs-mediated attenuation of CDDP-induced AKI. Conclusions: Gal-3 protects from CDDP-induced AKI by promoting TLR-2-dependent activation of IDO1/KYN pathway in renal DCs resulting in increased expansion of immunosuppressive Tregs in injured kidneys. Activation of Gal-3:TLR-2:IDO1 pathway in renal DCs should be further explored as new therapeutic approach for DC-based immunosuppression of inflammatory renal diseases." @default.
• W2972688853 created "2019-09-19" @default.
• W2972688853 creator A5005031112 @default.
• W2972688853 creator A5016290215 @default.
• W2972688853 creator A5026875028 @default.
• W2972688853 creator A5029402480 @default.
• W2972688853 creator A5029681438 @default.
• W2972688853 creator A5030705885 @default.
• W2972688853 creator A5045749487 @default.
• W2972688853 creator A5062544738 @default.
• W2972688853 creator A5064064837 @default.
• W2972688853 creator A5083635080 @default.
• W2972688853 date "2019-01-01" @default.
• W2972688853 modified "2023-09-30" @default.
• W2972688853 title "Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs" @default.
• W2972688853 cites W1480085362 @default.
• W2972688853 cites W1541174147 @default.
• W2972688853 cites W1592702771 @default.
• W2972688853 cites W1600560134 @default.
• W2972688853 cites W1832511462 @default.
• W2972688853 cites W1882571095 @default.
• W2972688853 cites W1889381783 @default.
• W2972688853 cites W1900702727 @default.
• W2972688853 cites W1965471441 @default.
• W2972688853 cites W1974836020 @default.
• W2972688853 cites W1976020912 @default.
• W2972688853 cites W1978523131 @default.
• W2972688853 cites W1993096008 @default.
• W2972688853 cites W1998226806 @default.
• W2972688853 cites W1998915656 @default.
• W2972688853 cites W2002534521 @default.
• W2972688853 cites W2016434952 @default.
• W2972688853 cites W2017717268 @default.
• W2972688853 cites W2022101399 @default.
• W2972688853 cites W2033792417 @default.
• W2972688853 cites W2051036708 @default.
• W2972688853 cites W2054166710 @default.
• W2972688853 cites W2061082542 @default.
• W2972688853 cites W2061460842 @default.
• W2972688853 cites W2068892733 @default.
• W2972688853 cites W2071604260 @default.
• W2972688853 cites W2074238760 @default.
• W2972688853 cites W2079010923 @default.
• W2972688853 cites W2097058099 @default.
• W2972688853 cites W2097494740 @default.
• W2972688853 cites W2098313871 @default.
• W2972688853 cites W2104355352 @default.
• W2972688853 cites W2108352961 @default.
• W2972688853 cites W2110432110 @default.
• W2972688853 cites W2115237497 @default.
• W2972688853 cites W2122441186 @default.
• W2972688853 cites W2122644281 @default.
• W2972688853 cites W2126728583 @default.
• W2972688853 cites W2127552400 @default.
• W2972688853 cites W2127785645 @default.
• W2972688853 cites W2127999139 @default.
• W2972688853 cites W2130381031 @default.
• W2972688853 cites W2134245211 @default.
• W2972688853 cites W2136049487 @default.
• W2972688853 cites W2136407994 @default.
• W2972688853 cites W2144675149 @default.
• W2972688853 cites W2147188198 @default.
• W2972688853 cites W2147915982 @default.
• W2972688853 cites W2148962636 @default.
• W2972688853 cites W2149190057 @default.
• W2972688853 cites W2157725506 @default.
• W2972688853 cites W2159554935 @default.
• W2972688853 cites W2281484774 @default.
• W2972688853 cites W2309368936 @default.
• W2972688853 cites W2317056325 @default.
• W2972688853 cites W2342100029 @default.
• W2972688853 cites W2471339379 @default.
• W2972688853 cites W2551119969 @default.
• W2972688853 cites W2556583129 @default.
• W2972688853 cites W2591115003 @default.
• W2972688853 cites W2603303879 @default.
• W2972688853 cites W2604619953 @default.
• W2972688853 cites W2741867373 @default.
• W2972688853 cites W2751029897 @default.
• W2972688853 cites W2751151357 @default.
• W2972688853 cites W2766025104 @default.
• W2972688853 cites W2782341620 @default.
• W2972688853 cites W2790965559 @default.
• W2972688853 cites W2792517138 @default.
• W2972688853 cites W2792699637 @default.
• W2972688853 cites W2885871071 @default.
• W2972688853 cites W2891654049 @default.
• W2972688853 cites W2894152312 @default.
• W2972688853 cites W2897224234 @default.
• W2972688853 cites W2899300228 @default.
• W2972688853 cites W2900934778 @default.
• W2972688853 cites W2904165696 @default.
• W2972688853 cites W2911553965 @default.
• W2972688853 cites W2911695870 @default.
• W2972688853 cites W2948133685 @default.
• W2972688853 doi "https://doi.org/10.7150/thno.33959" @default.
• W2972688853 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6735380" @default.
• W2972688853 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31534532" @default.

• next